What do you see that is solid about it apart from their balance...

What do you see that is solid about it apart from their balance sheet growing, which seems to be their go to every report. It is a good sign for a company obviously, but it seems to be the same focus point every time. Nice rise in revenue, but cost of materials is up massively and costs of employees. It wasn’t a bad result but I wouldn’t say it was great. No updates on any of the trials or the sixth indication they have been going in about for months and months. Good to see them spending a lot on r&d though. Maybe we might hear some updates this year if we are lucky.